Cargando…
Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort
INTRODUCTION: This study investigated five confirmed rheumatoid arthritis (RA) susceptibility genes/loci (HLA-DRB1, PTPN22, STAT4, OLIG3/TNFAIP3 and TRAF1/C5) for association with susceptibility and severity in an inception cohort. METHODS: The magnitude of association for each genotype was assessed...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888207/ https://www.ncbi.nlm.nih.gov/pubmed/20353580 http://dx.doi.org/10.1186/ar2969 |
_version_ | 1782182637144637440 |
---|---|
author | Morgan, Ann W Robinson, James I Conaghan, Philip G Martin, Stephen G Hensor, Elizabeth MA Morgan, Michael D Steiner, Lori Erlich, Henry A Gooi, Hock-Chye Barton, Anne Worthington, Jane Emery, Paul |
author_facet | Morgan, Ann W Robinson, James I Conaghan, Philip G Martin, Stephen G Hensor, Elizabeth MA Morgan, Michael D Steiner, Lori Erlich, Henry A Gooi, Hock-Chye Barton, Anne Worthington, Jane Emery, Paul |
author_sort | Morgan, Ann W |
collection | PubMed |
description | INTRODUCTION: This study investigated five confirmed rheumatoid arthritis (RA) susceptibility genes/loci (HLA-DRB1, PTPN22, STAT4, OLIG3/TNFAIP3 and TRAF1/C5) for association with susceptibility and severity in an inception cohort. METHODS: The magnitude of association for each genotype was assessed in 1,046 RA subjects from the Yorkshire Early RA cohort and in 5,968 healthy UK controls. Additional exploratory subanalyses were undertaken in subgroups defined by autoantibody status (rheumatoid factor and anti-cyclic citrullinated peptide) or disease severity (baseline articular erosions, Health Assessment Questionnaire (HAQ) score and swollen joint count (SJC)). RESULTS: In the total RA inception cohort, the HLA-DRB1 shared epitope (per-allele odds ratio (OR) = 2.1, trend P < 0.0001), PTPN22 (per-allele OR = 1.5, trend P < 0.0001), OLIG3/TNFAIP3 locus (per-allele OR = 1.2, trend P = 0.009) and TRAF1/C5 locus (per-allele OR = 1.1, trend P = 0.04) were associated with RA. The magnitude of association for these loci was increased in those patients who were autoantibody-positive. PTPN22 was associated with autoantibody-negative RA (per-allele OR = 1.3, trend P = 0.04). There was no evidence of association between these five genetic loci and baseline erosions or SJC in the total RA cohort, after adjustment for symptom duration. TRAF1/C5 was significantly associated with baseline HAQ, however, following adjustment for symptom duration (P trend = 0.03). CONCLUSIONS: These findings support the mounting evidence that different genetic loci are associated with autoantibody-positive and autoantibody-negative RA, possibly suggesting that many of the genes identified to date are associated with autoantibody production. Additional studies with a specific focus on autoantibody-negative RA will be needed to identify the genes predisposing to this RA subgroup. The TRAF1/C5 locus in particular warrants further investigation in RA as a potential disease severity locus. |
format | Text |
id | pubmed-2888207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28882072010-06-21 Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort Morgan, Ann W Robinson, James I Conaghan, Philip G Martin, Stephen G Hensor, Elizabeth MA Morgan, Michael D Steiner, Lori Erlich, Henry A Gooi, Hock-Chye Barton, Anne Worthington, Jane Emery, Paul Arthritis Res Ther Research article INTRODUCTION: This study investigated five confirmed rheumatoid arthritis (RA) susceptibility genes/loci (HLA-DRB1, PTPN22, STAT4, OLIG3/TNFAIP3 and TRAF1/C5) for association with susceptibility and severity in an inception cohort. METHODS: The magnitude of association for each genotype was assessed in 1,046 RA subjects from the Yorkshire Early RA cohort and in 5,968 healthy UK controls. Additional exploratory subanalyses were undertaken in subgroups defined by autoantibody status (rheumatoid factor and anti-cyclic citrullinated peptide) or disease severity (baseline articular erosions, Health Assessment Questionnaire (HAQ) score and swollen joint count (SJC)). RESULTS: In the total RA inception cohort, the HLA-DRB1 shared epitope (per-allele odds ratio (OR) = 2.1, trend P < 0.0001), PTPN22 (per-allele OR = 1.5, trend P < 0.0001), OLIG3/TNFAIP3 locus (per-allele OR = 1.2, trend P = 0.009) and TRAF1/C5 locus (per-allele OR = 1.1, trend P = 0.04) were associated with RA. The magnitude of association for these loci was increased in those patients who were autoantibody-positive. PTPN22 was associated with autoantibody-negative RA (per-allele OR = 1.3, trend P = 0.04). There was no evidence of association between these five genetic loci and baseline erosions or SJC in the total RA cohort, after adjustment for symptom duration. TRAF1/C5 was significantly associated with baseline HAQ, however, following adjustment for symptom duration (P trend = 0.03). CONCLUSIONS: These findings support the mounting evidence that different genetic loci are associated with autoantibody-positive and autoantibody-negative RA, possibly suggesting that many of the genes identified to date are associated with autoantibody production. Additional studies with a specific focus on autoantibody-negative RA will be needed to identify the genes predisposing to this RA subgroup. The TRAF1/C5 locus in particular warrants further investigation in RA as a potential disease severity locus. BioMed Central 2010 2010-03-30 /pmc/articles/PMC2888207/ /pubmed/20353580 http://dx.doi.org/10.1186/ar2969 Text en Copyright ©2010 Morgan et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research article Morgan, Ann W Robinson, James I Conaghan, Philip G Martin, Stephen G Hensor, Elizabeth MA Morgan, Michael D Steiner, Lori Erlich, Henry A Gooi, Hock-Chye Barton, Anne Worthington, Jane Emery, Paul Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort |
title | Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort |
title_full | Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort |
title_fullStr | Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort |
title_full_unstemmed | Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort |
title_short | Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort |
title_sort | evaluation of the rheumatoid arthritis susceptibility loci hla-drb1, ptpn22, olig3/tnfaip3, stat4 and traf1/c5 in an inception cohort |
topic | Research article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888207/ https://www.ncbi.nlm.nih.gov/pubmed/20353580 http://dx.doi.org/10.1186/ar2969 |
work_keys_str_mv | AT morganannw evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT robinsonjamesi evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT conaghanphilipg evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT martinstepheng evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT hensorelizabethma evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT morganmichaeld evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT steinerlori evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT erlichhenrya evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT gooihockchye evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT bartonanne evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT worthingtonjane evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort AT emerypaul evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort |